KRAS and cholangiocarcinoma: To validate our finding of distinct mRNA-based similarities between cholangiocarcinoma and KRAS wildtype mPDAC, we leveraged RNAseq data for cholangiocarcinoma (n = 25) and mPDAC (n = 46) samples from the Hartwig validation dataset and performed an identical consensus clustering analysis.